TP53 and neoplasm: Comparative analyses of matched P and tumor specimens from liver metastases after standard first-line treatment (M) showed the same mutations in 71.4% of the patients, whereas in 28.6%, metastasis private mutations were found in M. Of note, these additional mutations in the ATM, TP53, POLE genes do not reflect typical resistance mutations in solid tumors.